Morningstar
•
Aug 19, 2026
Merck & Co., Inc.: Moderna and Merck: Intismeran's Positive Phase 3 Readout Confirms mRNA Potential in Oncology
Summary
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: The Procter & Gamble Company
Aug 31, 2026
•
PG
Weekly Stock List
Aug 31, 2026
•
TGT, CVS, DE, LNG, EL, BJ, LEA, PWR, WMB, JCI, APA, SJM, XYZ, ALC, LLY, ANF, CMI, PLTR, WMT, VGNT
Daily Spotlight: Value Versus Growth Investing
Aug 28, 2026
•
BMY
Analyst Report: Gilead Sciences, Inc.
Aug 25, 2026
•
GILD
Analyst Report: Verizon Communications Inc.
Aug 25, 2026
•
VZ
